Physician profile
David J Weldon
NPI 1023043064
$1,821.20
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $285 · 2021: $951 · 2022: $149.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $373.16 | 2019-2022 | |
| Abbvie INC. | $284.07 | 2021-2022 | |
| Abbott Laboratories | $195.51 | 2021 | |
| Novo Nordisk INC | $192.49 | 2019-2022 | |
| Amgen INC. | $108.54 | 2019-2021 | |
| Amarin Pharma, INC. | $106.57 | 2019-2021 | |
| Astellas Pharma US INC | $103.75 | 2019-2022 | |
| Pfizer INC. | $90.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.08 | 2019-2020 | |
| Lilly USA, LLC | $59.84 | 2019-2021 | |
| Esperion Therapeutics, INC. | $56.06 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.07 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $33.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.07 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.96 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vistapharm, INC. | $15.39 | 2021 | |
| Phadia US INC. | $13.00 | 2022 | |
| Merck Sharp & Dohme LLC | $12.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.